Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Mario Luca Morieri, Angelo Avogaro & Gian Paolo Fadini. (2020) Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice. Diabetes, Metabolic Syndrome and Obesity 13, pages 4221-4234.
Read now
Read now
André J. Scheen. (2017) Dulaglutide for the treatment of type 2 diabetes. Expert Opinion on Biological Therapy 17:4, pages 485-496.
Read now
Read now
Articles from other publishers (10)
Yuqin Zhang, Zhihua Qu, Ting Lu, Xiaowen Shao, Meili Cai, Diliqingna Dilimulati, Xinxin Gao, Weiqing Mao, Fan Hu, Lili Su, Qiong Liao, Ting Han, Manna Zhang & Shen Qu. (2023) Effects of a Dulaglutide plus Calorie-Restricted Diet versus a Calorie-Restricted Diet on Visceral Fat and Metabolic Profiles in Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial. Nutrients 15:3, pages 556.
Crossref
Crossref
Ulrich Werner, Maximilian Bielohuby, Marcus Korn, Jens Riedel, Martin Will & María Méndez. (2022)
Preclinical pharmacology of
RA15127343
: In vitro and in vivo activity of a novel ultralong‐acting basal insulin
. Diabetes, Obesity and Metabolism 24:12, pages 2411-2419.
Crossref
Crossref
William Polonsky, Cory Gamble, Neeraj Iyer, Mona Martin & Carol Hamersky. (2021) Exploring Why People With Type 2 Diabetes Do or Do Not Persist With Glucagon-Like Peptide-1 Receptor Agonist Therapy: A Qualitative Study. Diabetes Spectrum 34:2, pages 175-183.
Crossref
Crossref
Ann‐Marie Svensson, Anders Toll, Jeremie Lebrec, Mervete Miftaraj, Stefan Franzén & Björn Eliasson. (2020) Treatment persistence in patients with type 2 diabetes treated with glucagon‐like peptide‐1 receptor agonists in clinical practice in Sweden. Diabetes, Obesity and Metabolism 23:3, pages 720-729.
Crossref
Crossref
Beáta E. Nagy, Brigitta Munkácsi & Karolina Eszter Kovács. (2021) Factors Influencing Adherence Among Youth with Type-1-Diabetes Mellitus - The Hungarian Case. Current Diabetes Reviews 17:2, pages 222-232.
Crossref
Crossref
Antonio C. Bossi, Valentina De Mori, Cristiana Scaranna, Giovanni Veronesi, Giuseppe Lepore, Agosti Barbara, Bellante Rosalia, Belviso Antonio, Berzi Denise, Bonfadini Silvia, Casati Sergio, Colzani Milena, Ettori Stefano, Franzetti Ivano, Gaiti Margherita, Ghilardi Giosuè, Lovati Elisabetta, Lucotti Pietro, Malighetti Maria Elena, Manzoni Giuseppina, Meregalli Giancarla, Orsi Emanuela, Palmieri Eva, Querci Fabrizio, Ragni Giorgio, Rinaldi Joselita, Severgnini Silvia Cecilia, Zenoni Luca, Bertola Davide Pietro, Buizza Mario, Calebitch Silvia, Creanza Annalisa, D’Angelo Francesco, Magri Viviana, Mantovani Linneo Enzo, Mascadri Cristina, Pagani Micol, Paroli Antonio, Richini Donata, Rignanese Giovanni & Zarra Emanuela. (2020) ANDREW: A Multicenter, Prospective, Observational Study in Patients with Type 2 Diabetes on Persistent Treatment with Dulaglutide. Diabetes Therapy 11:11, pages 2677-2690.
Crossref
Crossref
Mario Luca Morieri, Mauro Rigato, Vera Frison, Natalino Simioni, Michele D'Ambrosio, Federica Tadiotto, Agostino Paccagnella, Annunziata Lapolla, Angelo Avogaro & Gian Paolo Fadini. (2020) Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies. Metabolism 106, pages 154190.
Crossref
Crossref
Richard E Pratley, Vanita R Aroda, Ildiko Lingvay, Jörg Lüdemann, Camilla Andreassen, Andrea Navarria & Adie Viljoen. (2018) Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. The Lancet Diabetes & Endocrinology 6:4, pages 275-286.
Crossref
Crossref
Maria Yu, Kate Van Brunt, Zvonko Milicevic, Oralee Varnado & Kristina S. Boye. (2017) Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9). Clinical Therapeutics 39:11, pages 2284-2295.
Crossref
Crossref
Carlos Alatorre, Laura Fernández Landó, Maria Yu, Katelyn Brown, Leslie Montejano, Paul Juneau, Reema Mody & Ralph Swindle. (2017) Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide. Diabetes, Obesity and Metabolism 19:7, pages 953-961.
Crossref
Crossref